The impaired response of nasal epithelial cells to microplastic stimulation in asthma and COPD

Magdalena Paplińska-Goryca1, Paulina Misiukiewicz-Stępień2, Monika Wróbel2

  • 1Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland. magdalena.paplinska@wum.edu.pl.

Scientific Reports
|February 5, 2025
PubMed

Insights

Airborne microplastics harm lung tissue. Polyamide fibres differentially affect airway cells in asthma and COPD, increasing susceptibility to damage and altering biological pathways. Further research is needed.

Area of Science:

  • Environmental Health
  • Pulmonology
  • Immunology

Background:

  • Airborne microplastics pose a growing health concern, with potential to cause lung injury.
  • Polyamide fibres are common microplastic pollutants.
  • Obstructive lung diseases like asthma and COPD involve airway inflammation and tissue damage.

Purpose of the Study:

  • To investigate the biological effects of polyamide microplastic fibres on nasal epithelium.
  • To compare responses in control, asthma, and COPD patient-derived cells.
  • To identify molecular and cellular changes induced by microplastic exposure.

Main Methods:

  • Nasal epithelial cells were co-cultured with monocyte-derived macrophages.
  • Cells were exposed to polyamide fibres for 48 hours.
  • Gene expression (DEGs), cytokine secretion, and Gene Ontology pathways were analyzed.

Main Results:

  • Microplastic exposure caused significant gene expression changes, particularly in asthma (309 DEGs) and COPD (22 DEGs) co-cultures.
  • Inflammatory cytokine IL-8 was induced in controls and asthmatics, but less so than PM2.5.
  • Affected pathways included sterol biosynthesis (asthma) and cell motility/chemokine signaling (COPD).

Conclusions:

  • Microplastic exposure alters airway epithelial cell responses distinctively in asthma and COPD.
  • Asthmatic and COPD cells exhibit increased susceptibility to microplastic fibre-induced damage.
  • Findings link microplastic exposure to Th2 inflammation, stress responses, and potential carcinogenesis.

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
343
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.7K
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
233
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
344